This article is more than 5 years old. Information may no longer be current.
Neonates metabolized oseltamivir course well
Click Here to Manage Email Alerts
CHICAGO — Thirteen neonates who were exposed to the H1N1 influenza virus during the height of the 2009 pandemic and received oseltamivir as prophylaxis did not develop influenza and metabolized the medication well, according to a study presented here during the 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy.
Researchers from the Hellenic Center for Disease Control and Prevention in Athens, Greece, examined the pharmacokinetics of a 10-day course of oseltamivir (Tamiflu, Roche), administered at 1 mg/kg twice daily. Eight of the neonates had been admitted to a hospital for bronchiolitis, and six of those infants also had respiratory syncytial. Two of the infants were admitted for fever, and the other three infants were admitted for Kasabach-Merritt syndrome, neonatal jaundice and intrauterine growth restriction, respectively.
According to the researchers, none of the babies developed influenza, but four of them developed mild gastrointestinal symptoms, including loose stools, diarrheas and vomiting. “Mean Cmax concentrations for oseltamivir and oseltamivir carboxylate were lower than those reported in children [aged] 1 to 5 years,” they said.
“Further prospective studies with large number of patients are needed,” study researcher Helena Maltezou, MD, PhD, told Infectious Diseases in Children.
For more information:
- Maltezou HC. #V-1557a. Presented at: 51st ICAAC; Sept. 17-20, 2011; Chicago.
 |
Follow the PediatricSuperSite.com on Twitter. |